Glen Eagle Advisors’s Labcorp LH Stock Holding History

Glen Eagle Advisors’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.41K	Buy	32 +1	+3%	+$271	﹤0.01%	693
2025 Q4	$7.89K	Hold	31	–	–	﹤0.01%	724
2025 Q3	$9.01K	Buy	31 +11	+55%	+$2.95K	﹤0.01%	710
2025 Q2	$5.33K	Hold	20	–	–	﹤0.01%	723
2025 Q1	$4.72K	Hold	20	–	–	﹤0.01%	733
2024 Q4	$4.63K	Hold	20	–	–	﹤0.01%	757
2024 Q3	$4.5K	Buy	+20	New	+$4.4K	﹤0.01%	774
2023 Q1	–	Sell	-3	Closed	-$706	–	1163
2022 Q4	$706	Buy	+3	New	+$586	﹤0.01%	1051
2021 Q3	–	Sell	-22	Closed	-$5.24K	–	1081
2021 Q2	$5.24K	Hold	22	–	–	﹤0.01%	807
2021 Q1	$4.85K	Hold	22	–	–	﹤0.01%	776
2020 Q4	$3.87K	Hold	22	–	–	﹤0.01%	774
2020 Q3	$3.58K	Hold	22	–	–	﹤0.01%	734
2020 Q2	$3.16K	Hold	22	–	–	﹤0.01%	723
2020 Q1	$2.4K	Hold	22	–	–	﹤0.01%	698
2019 Q4	$3.21K	Hold	22	–	–	﹤0.01%	751
2019 Q3	$3.19K	Buy	+22	New	+$3.21K	﹤0.01%	680

Other funds holding LH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glen Eagle Advisors's LH Position: Q1 2026 in Review

Glen Eagle Advisors increased its Labcorp (LH) stake by 3.2% in Q1 2026, buying an estimated $271 and bringing the position to 32 shares worth $8.41K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Glen Eagle Advisors first reported a position in LH in Q3 2019 and has held it in 16 quarters since. The position peaked at $9.01K in Q3 2025. 1,031 funds tracked by Wall St. Rank hold LH as of Q1 2026.

Glen Eagle Advisors held 32 shares of Labcorp worth $8.41K as of Q1 2026.
Glen Eagle Advisors bought 1 Labcorp share in Q1 2026, an estimated $271.
Labcorp made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #693 holding.
Glen Eagle Advisors first reported a position in Labcorp in Q3 2019 and has held it in 16 quarters since.
Glen Eagle Advisors's Labcorp position peaked at $9.01K in Q3 2025.
1,031 funds tracked by Wall St. Rank held Labcorp as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.